Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomas

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|12|2078-2082

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.12, 2015-06, pp. : 2078-2082

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 2, 2013-06 ,pp. : 93-100

Bentham Science Publishers

Access to resources Recommend Favorite

Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib

By  

CANCER, Vol. 120, Iss. 4, 2014-02 ,pp. : 530-536

John Wiley & Sons Inc

Access to resources Recommend Favorite

Performance of EGFR mutant‐specific antibodies in different cytological preparations: a validation study

By  

CYTOPATHOLOGY, Vol. 26, Iss. 2, 2015-04 ,pp. : 99-105

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression

By  

Oncology Research and Treatment, Vol. 39, Iss. 10, 2016-09 ,pp. : 605-614

Karger

Access to resources Recommend Favorite